OBJECTIVES: The goal of this study was to assess serial changes in patient health-related quality of life (HRQOL) over time and identify predictors of patient benefit. BACKGROUND: Severe aortic stenosis reduces the length and quality of a patient's life. Transcatheter aortic valve implantation (TAVI) is superior to standard medical therapy and noninferior to surgical aortic valve replacement for 1-year mortality. HRQOL is an important outcome measure for which there is limited evidence in TAVI populations. METHODS: A total of 102 patients (mean age 80 ± 0.6 years; 49% male) undergoing TAVI consented to participate. Two HRQOL questionnaires-the social functioning (SF)-12v2 with physical component summaries (PCS) and mental component summaries (MCS) and the EQ-5D (with a visual analog scale [VAS])-were completed at baseline, 30 days, 6 months, and 1 year according to the recommendations of the Valve Academic Research Consortium. A SF-6D utility measure was calculated from the SF-12 survey. RESULTS: HRQOL significantly improved over 1 year (PCS p = 0.02; EQ-5D p = 0.02; VAS p = 0.01; SF-6D p = 0.03), becoming similar to age-adjusted U.S. population norms. The greatest change occurred from baseline to 30 days (p < 0.001), with further significant improvements to 6 months (p < 0.01). An insignificant decline occurred between 6 months and 1 year (p > 0.05), but a linear pattern of change remained for PCS, EQ-5D, and VAS (p < 0.05). Male sex (SF-6D p = 0.01) and increased operator experience (PCS, EQ-5D, and VAS p < 0.05) were independent predictors of a greater improvement in HRQOL. CONCLUSIONS: HRQOL significantly improved early after TAVI and was maintained out to 1 year. Patient factors, procedural complications, and operator experience are predictors of health benefit at 1 year.
OBJECTIVES: The goal of this study was to assess serial changes in patient health-related quality of life (HRQOL) over time and identify predictors of patient benefit. BACKGROUND: Severe aortic stenosis reduces the length and quality of a patient's life. Transcatheter aortic valve implantation (TAVI) is superior to standard medical therapy and noninferior to surgical aortic valve replacement for 1-year mortality. HRQOL is an important outcome measure for which there is limited evidence in TAVI populations. METHODS: A total of 102 patients (mean age 80 ± 0.6 years; 49% male) undergoing TAVI consented to participate. Two HRQOL questionnaires-the social functioning (SF)-12v2 with physical component summaries (PCS) and mental component summaries (MCS) and the EQ-5D (with a visual analog scale [VAS])-were completed at baseline, 30 days, 6 months, and 1 year according to the recommendations of the Valve Academic Research Consortium. A SF-6D utility measure was calculated from the SF-12 survey. RESULTS: HRQOL significantly improved over 1 year (PCS p = 0.02; EQ-5D p = 0.02; VAS p = 0.01; SF-6D p = 0.03), becoming similar to age-adjusted U.S. population norms. The greatest change occurred from baseline to 30 days (p < 0.001), with further significant improvements to 6 months (p < 0.01). An insignificant decline occurred between 6 months and 1 year (p > 0.05), but a linear pattern of change remained for PCS, EQ-5D, and VAS (p < 0.05). Male sex (SF-6D p = 0.01) and increased operator experience (PCS, EQ-5D, and VAS p < 0.05) were independent predictors of a greater improvement in HRQOL. CONCLUSIONS: HRQOL significantly improved early after TAVI and was maintained out to 1 year. Patient factors, procedural complications, and operator experience are predictors of health benefit at 1 year.
Authors: Janine Biermann; Martin Horack; Philipp Kahlert; Steffen Schneider; Georg Nickenig; Ralf Zahn; Jochen Senges; Raimund Erbel; Jürgen Wasem; Till Neumann Journal: Clin Res Cardiol Date: 2015-04-21 Impact factor: 5.460
Authors: Ruben L Osnabrugge; Suzanne V Arnold; Matthew R Reynolds; Elizabeth A Magnuson; Kaijun Wang; Vincent A Gaudiani; Robert C Stoler; Thomas A Burdon; Neal Kleiman; Michael J Reardon; David H Adams; Jeffrey J Popma; David J Cohen Journal: JACC Cardiovasc Interv Date: 2015-02 Impact factor: 11.195
Authors: Moritz Seiffert; Jan-Malte Sinning; Alexander Meyer; Sandra Wilde; Lenard Conradi; Mariuca Vasa-Nicotera; Alexander Ghanem; Jörg Kempfert; Christoph Hammerstingl; Francisco M Ojeda; Won-Keun Kim; Dietmar H Koschyk; Johannes Schirmer; Stephan Baldus; Eberhard Grube; Helge Möllmann; Hermann Reichenspurner; Georg Nickenig; Stefan Blankenberg; Patrick Diemert; Hendrik Treede; Thomas Walther; Nikos Werner; Renate B Schnabel Journal: Clin Res Cardiol Date: 2014-03-19 Impact factor: 5.460
Authors: Marjo Jag De Ronde-Tillmans; Tom Aj de Jager; Jeannette A Goudzwaard; Nahid El Faquir; Nicolas M van Mieghem; Felix Zijlstra; Elisabeth Mwj Utens; Francesco Us Mattace-Raso; Mattie J Lenzen; Peter Pt de Jaegere Journal: J Geriatr Cardiol Date: 2018-04 Impact factor: 3.327
Authors: Caroline A Kim; Suraj P Rasania; Jonathan Afilalo; Jeffrey J Popma; Lewis A Lipsitz; Dae Hyun Kim Journal: Ann Intern Med Date: 2014-02-18 Impact factor: 25.391
Authors: Tarique Al Musa; Akhlaque Uddin; Catherine Loveday; Laura E Dobson; Mark Igra; Fiona Richards; Peter P Swoboda; Anvesha Singh; Pankaj Garg; James R J Foley; Graham J Fent; Anthony J P Goddard; Christopher Malkin; Sven Plein; Daniel J Blackman; Gerald P McCann; John P Greenwood Journal: BMJ Open Date: 2019-01-21 Impact factor: 2.692